Document Detail


Treatment of tubal pregnancy in the netherlands: an economic comparison of systemic methotrexate administration and laparoscopic salpingostomy.
MedLine Citation:
PMID:  10521759     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: This study was undertaken to compare from a societal perspective the costs of systemic methotrexate administration with those of laparoscopic salpingostomy for the treatment of patients with tubal pregnancy. STUDY DESIGN: An economic evaluation was set up in tandem with a multicenter randomized clinical trial that compared systemic methotrexate administration and laparoscopic salpingostomy for the treatment of 100 hemodynamically stable patients with laparoscopically confirmed unruptured tubal pregnancy. Data on resources used for treatment and lost production time were prospectively collected and costs of both treatments were calculated by multiplying actual expenses for resource units at a single center and resource unit use measured in all centers. Costs were originally calculated in Dutch guilders and converted to US dollars at a rate of 1.67 guilders/$1. RESULTS: Because clinical outcomes of the trial were equivalent for the 2 strategies a cost-minimization analysis was done. Mean total costs per patient were $5721 for systemic methotrexate administration and $4066 for laparoscopic salpingostomy, with a mean difference of $1655 (95% confidence interval, $906-$2414). Costs of systemic methotrexate administration were similar to those of salpingostomy for patients in whom the initial serum human chorionic gonadotropin concentration was <1500 IU/L, a cutoff value that had not been previously hypothesized. In a scenario without a confirmatory laparoscopy, in which transvaginal ultrasonography and serial repeated serum human chorionic gonadotropin measurements were assumed to be as accurate as laparoscopy, systemic methotrexate therapy would have reduced total cost by $1500 for a patient with an initial serum human chorionic gonadotropin concentration of <1500 IU/L. In such a scenario total costs would have been similar for a patient with an initial serum human chorionic gonadotropin concentration in the range of 1500 to 3000 IU/L, whereas systemic methotrexate administration would be more costly for a patient with an initial serum human chorionic gonadotropin concentration of >3000 IU/L. CONCLUSIONS: Although systemic methotrexate administration is safe and effective for the treatment of tubal pregnancy, it does not necessarily reduce costs. Systemic methotrexate therapy could reduce costs if administered to patients with low initial serum human chorionic gonadotropin concentrations without confirmatory laparoscopy.
Authors:
B W Mol; P J Hajenius; S Engelsbel; W M Ankum; D J Hemrika; F Van der Veen; P M Bossuyt
Related Documents :
12012889 - Multiple-dose methotrexate for pregnancy in a cesarean section scar. a case report.
22223909 - Anaesthetic management for emergency caesarean section in a patient with an untreated r...
12198869 - Changes in alveolar morphology during open bite treatment and prediction of treatment r...
8582999 - Successful treatment of an advanced interstitial pregnancy by sequential systemic and l...
8803819 - Unilateral internuclear ophthalmoplegia and ipsiversive torsional nystagmus.
24450299 - Microbial load of umbilical cord blood ureaplasma species and mycoplasma hominis in pre...
16079989 - Diminished embryonic movements of developing embryo by direct exposure of sidestream wh...
6626129 - Livestock production on masai group ranches. 2. growth and liveweight in goats and shee...
9546509 - First-trimester transabdominal fetal echocardiography.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  181     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1999 Oct 
Date Detail:
Created Date:  1999-11-18     Completed Date:  1999-11-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  945-51     Citation Subset:  AIM; IM    
Affiliation:
Department of Clinical Epidemiology, University of Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Chorionic Gonadotropin / blood
Female
Gestational Age
Health Care Costs*
Humans
Laparoscopy / economics*
Methotrexate / economics,  therapeutic use*
Netherlands
Pregnancy
Pregnancy, Tubal / drug therapy*,  surgery*,  ultrasonography
Prospective Studies
Salpingostomy / economics*
Chemical
Reg. No./Substance:
0/Chorionic Gonadotropin; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The association of interleukin 6 with clinical and laboratory parameters of acute pelvic inflammator...
Next Document:  The pattern of infertility diagnoses in women of advanced reproductive age.